These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 7670225)

  • 41. Measles in developing countries. Part II. The predicted impact of mass vaccination.
    McLean AR; Anderson RM
    Epidemiol Infect; 1988 Jun; 100(3):419-42. PubMed ID: 3378585
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Resurgence of the measles epidemic: situation in Minas Gerais, Brazil].
    Oliveira MT; Caiaffa WT
    Rev Panam Salud Publica; 1998 Oct; 4(4):252-7. PubMed ID: 9924508
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Measles vaccination coverage among five-year-old children: implications for disease elimination in Australia.
    Lawrence GL; MacIntyre CR; Hull BP; McIntyre PB
    Aust N Z J Public Health; 2003; 27(4):413-8. PubMed ID: 14705304
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Optimum age for measles immunization in Romania.
    Biberi-Moroeanu S; Tiţeica-Boldeanu M; Munţiu A; Petrenco M; Suter C
    Virologie; 1986; 37(1):3-8. PubMed ID: 3962178
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Measles vaccination with split vaccines and living vaccines (author's transl)].
    Stehr K; Enders-Ruckle G; Spiess H
    MMW Munch Med Wochenschr; 1975 Jul; 117(27):1159-64. PubMed ID: 808710
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pulse mass measles vaccination across age cohorts.
    Agur Z; Cojocaru L; Mazor G; Anderson RM; Danon YL
    Proc Natl Acad Sci U S A; 1993 Dec; 90(24):11698-702. PubMed ID: 8265611
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Measles elimination in the Americas: a comparison between countries with a one-dose and two-dose routine vaccination schedule.
    Sever AE; Rainey JJ; Zell ER; Hennessey K; Uzicanin A; Castillo-Solórzano C; Dietz V
    J Infect Dis; 2011 Sep; 204 Suppl 2():S748-55. PubMed ID: 21954277
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Estimation of the Population Susceptibility Against Measles in Slovakia.
    Zibolenová J; Chladná Z; Švihrová V; Baška T; Waczulíková I; Hudečková H
    Cent Eur J Public Health; 2017 Mar; 25(1):46-54. PubMed ID: 28399355
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus.
    Christenson B; Böttiger M
    Vaccine; 1994 Feb; 12(2):129-33. PubMed ID: 8147093
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Timing of measles immunization and effective population vaccine coverage.
    Bielicki JA; Achermann R; Berger C
    Pediatrics; 2012 Sep; 130(3):e600-6. PubMed ID: 22908102
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Measles immunization: early two-doses policy experience.
    al-Mazrou YY; al-Jeffri M; Ahmed OM; Aziz KM; Mishkas AH
    J Trop Pediatr; 1999 Apr; 45(2):98-104. PubMed ID: 10341504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Study on the long-term observation of measles vaccine immunity. 1. End results of vaccination and re-vaccination].
    Tsukada Y
    Nihon Shonika Gakkai Zasshi; 1968 Apr; 72(4):473-87. PubMed ID: 5692409
    [No Abstract]   [Full Text] [Related]  

  • 53. Preventing epidemics with age-specific vaccination schedules.
    Becker NG; Bahrampour A
    Math Biosci; 1997 Jun; 142(2):63-77. PubMed ID: 9159058
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Watson JC; Hadler SC; Dykewicz CA; Reef S; Phillips L
    MMWR Recomm Rep; 1998 May; 47(RR-8):1-57. PubMed ID: 9639369
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Measles elimination: old and new challenges?
    Muller CP
    Vaccine; 2001 Mar; 19(17-19):2258-61. PubMed ID: 11257344
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The effect of heterogeneity in measles vaccination on population immunity.
    Glass K; Kappey K; Grenfell BT
    Epidemiol Infect; 2004 Aug; 132(4):675-83. PubMed ID: 15310169
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Seroresponse to the second measles vaccine dose at school entry in Qassim province, Saudi Arabia.
    Khalil MK; Nadrah HM; Al Yahia OA; ElGhazali G
    East Mediterr Health J; 2011 Mar; 17(3):191-5. PubMed ID: 21735958
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Progress Toward Measles Elimination - Pakistan, 2000-2018.
    Mere MO; Goodson JL; Chandio AK; Rana MS; Hasan Q; Teleb N; Alexander JP
    MMWR Morb Mortal Wkly Rep; 2019 Jun; 68(22):505-510. PubMed ID: 31170125
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Single or double dose of vaccine needed for the eradication of measles in Spain?].
    Vitoria Miñana I; Morales Suárez-Varela M; Cotanda Gutiérrez P; Asensi Botet F
    An Esp Pediatr; 1993 Feb; 38(2):130-4. PubMed ID: 8439098
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measles vaccine: a 27-year follow-up.
    Ramsay ME; Moffatt D; O'Connor M
    Epidemiol Infect; 1994 Apr; 112(2):409-12. PubMed ID: 8150015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.